Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390686 | 0.85 | RIPK1 (0.41) | RIPK1 | |
| SCHEMBL2392751 | 0.84 | KDM4E (0.47) | BRD4RIPK1 | |
| SCHEMBL9058282 | 0.83 | KDM1A (0.48) | — | |
| SCHEMBL2395578 | 0.83 | BRD4 (0.45) | BRD4RIPK1SLC6A2SLC6A4 | |
| SCHEMBL2395587 | 0.82 | SMN1; SMN2 (0.47) | BRD4RIPK1SLC6A2SLC6A4 | |
| SCHEMBL2393290 | 0.81 | NAAA (0.51) | — | |
| SCHEMBL14523185 | 0.79 | SCN9A (0.43) | SCN9A | |
| SCHEMBL2390705 | 0.79 | KDM4E (0.43) | BRD4RIPK1 | |
| SCHEMBL13625662 | 0.78 | MAPT (0.43) | RIPK1 | |
| SCHEMBL2391310 | 0.77 | HTT (0.40) | RIPK1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431702-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431702-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120309782-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309782-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8309729-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309729-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120214838-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214838-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-8188279-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188279-B2 | Therapeutically useful substituted hydropyrido [3,2,1-ij] quinoline compounds | ALLERGAN, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110237797-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237797-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20100009985-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009985-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009985-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| WO-2009137681-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-IJ] QUINOLINE COMPOUNDS | ALLERGAN, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214838-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | BRD4 411/4885SCN9A 2392/4885SCD 3703/4885 |
| US-20110237797-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | BRD4 411/4885SCN9A 2392/4885SCD 3703/4885 |
| US-20120309782-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | BRD4 411/4885SCN9A 2392/4885SCD 3703/4885 |
| US-20100009985-A1 | THERAPEUTICALLY USEFUL SUBSTITUTED HYDROPYRIDO [3,2,1-ij] QUINOLINE COMPOUNDS | NQO2, NDUFA3, NDUFB7 | BRD4 411/4885SCN9A 2392/4885SCD 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.